<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981045</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT09030</org_study_id>
    <nct_id>NCT00981045</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function</brief_title>
  <acronym>REPAIR-IDA</acronym>
  <official_title>Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine the efficacy and safety (cardiovascular) of
      an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron
      sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal
      function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.</measure>
    <time_frame>Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.</measure>
    <time_frame>Day 120</time_frame>
    <description>The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2561</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Impaired Renal Function</condition>
  <arm_group>
    <arm_group_label>Ferric Carboxymaltose (FCM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron Sucrose (Venofer)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 doses of 200 mg for a total cumulative dose of 1000 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose (FCM)</intervention_name>
    <description>2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg</description>
    <arm_group_label>Ferric Carboxymaltose (FCM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose (Venofer)</intervention_name>
    <description>5 doses of 200 mg for a total cumulative dose of 1000 mg</description>
    <arm_group_label>Iron Sucrose (Venofer)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects &gt; or = to 18 years of age.

          -  Chronically impaired renal function.

          -  Screening visit central laboratory hemoglobin &lt; or = to 11.5 g/dL.

          -  Screening ferritin &lt; or = to 100 ng/mL or &lt; or = to 300 when transferrin saturation
             (TSAT) is &lt; or = to 30%.

          -  If on an erythropoiesis stimulating agent(ESA) a stable dose (+/- 20%) for 4 weeks
             prior to randomization.

        Exclusion Criteria:

          -  Known hypersensitivity reaction to any component of ferric carboxymaltose (FCM) or
             Venofer.

          -  Previously randomized in a clinical study of Ferric Carboxymaltose (FCM).

          -  Requires dialysis for treatment of chronic kidney disease OR is being considered for
             initiation of dialysis during the time period of this trial.

          -  No evidence of iron deficiency.

          -  Any non-viral infection.

          -  AST or ALT at screening as determined by central labs greater than 1.5 times the upper
             limit of normal.

          -  Known positive hepatitis with evidence of active disease.

          -  Received an investigational drug within 30 days of screening.

          -  Alcohol or drug abuse within the past 6 months.

          -  Hemochromatosis or other iron storage disorders.

          -  Estimated life expectancy of less than 6 months, or for cancer patients, an ECOG
             Performance Status greater than 1.

          -  Any other laboratory abnormality, medical condition or psychiatric disorder which in
             the opinion of the investigator would put the subject's disease management at risk or
             may result in the subject being unable to comply with study requirements.

          -  Pregnant or sexually-active female subjects who are not willing to use an acceptable
             form of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Luitpold Pharmaceuticals, Inc.</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>August 14, 2013</results_first_submitted>
  <results_first_submitted_qc>August 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2013</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>04-Sept-2009 through 15-Jun-2011; Hospitals and Medical Clinics</recruitment_details>
      <pre_assignment_details>14 subjects randomized to FCM and 9 subjects randomized to Venofer were discontinued prior to dosing due to subject request or selection criteria/study compliance reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferric Carboxymaltose (FCM)</title>
          <description>Ferric Carboxymaltose (FCM) : 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg</description>
        </group>
        <group group_id="P2">
          <title>Iron Sucrose (Venofer)</title>
          <description>Iron Sucrose (Venofer) : 5 doses of 200 mg for a total cumulative dose of 1000 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1290"/>
                <participants group_id="P2" count="1294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1276"/>
                <participants group_id="P2" count="1285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>14 subjects randomized to receive FCM and 9 subjects randomized to receive Venefor were randomized but discontinued prior to dosing due to subject request or selection criteria/study compliance reasons.</population>
      <group_list>
        <group group_id="B1">
          <title>Ferric Carboxymaltose (FCM)</title>
          <description>Ferric Carboxymaltose (FCM) : 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg</description>
        </group>
        <group group_id="B2">
          <title>Iron Sucrose (Venofer)</title>
          <description>Iron Sucrose (Venofer) : 5 doses of 200 mg for a total cumulative dose of 1000 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1276"/>
            <count group_id="B2" value="1285"/>
            <count group_id="B3" value="2561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="468"/>
                    <measurement group_id="B2" value="500"/>
                    <measurement group_id="B3" value="968"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="808"/>
                    <measurement group_id="B2" value="785"/>
                    <measurement group_id="B3" value="1593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="13.00"/>
                    <measurement group_id="B2" value="67.2" spread="13.00"/>
                    <measurement group_id="B3" value="67.3" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="810"/>
                    <measurement group_id="B2" value="818"/>
                    <measurement group_id="B3" value="1628"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="466"/>
                    <measurement group_id="B2" value="467"/>
                    <measurement group_id="B3" value="933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1276"/>
                    <measurement group_id="B2" value="1285"/>
                    <measurement group_id="B3" value="2561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.</title>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Ferric Carboxymaltose (FCM) : 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (Venofer)</title>
            <description>Iron Sucrose (Venofer) : 5 doses of 200 mg for a total cumulative dose of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1249"/>
                <count group_id="O2" value="1244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="1.044"/>
                    <measurement group_id="O2" value="0.92" spread="0.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.</title>
        <description>The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.</description>
        <time_frame>Day 120</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Ferric Carboxymaltose (FCM) : 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (Venofer)</title>
            <description>Iron Sucrose (Venofer) : 5 doses of 200 mg for a total cumulative dose of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.</title>
          <description>The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1276"/>
                <count group_id="O2" value="1285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>September 4, 2009 through June 15, 2011</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ferric Carboxymaltose (FCM)</title>
          <description>Ferric Carboxymaltose (FCM) : 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg</description>
        </group>
        <group group_id="E2">
          <title>Iron Sucrose (Venofer)</title>
          <description>Iron Sucrose (Venofer) : 5 doses of 200 mg for a total cumulative dose of 1000 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Ischemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Superventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Fecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gastritis hemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Intestinal ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Generalized edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pancreas transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Staphy;ococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Urostomy complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>International normalized ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Liver function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypovolemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypoglycemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Dyspnea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angiedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="305" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="1276"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Falone, MD</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>610-650-4200</phone>
      <email>mfalone@luitpold.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

